Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease
A dose–response meta-analysis
Li Ren, MD, Jie Yi, MD, Jing Yang, MD, Peng Li, MD, Xueyan Cheng, MD, Peixian Mao, MD∗

Abstract
Previous studies have indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) use is associated with Parkinson disease risk, but presented controversial results.

Medline, Embase, Web of Science, and the Cochrane Database were searched update to November 2017. Key data were extracted from eligible studies. A dose–response meta-analysis was conducted for synthesizing data from eligible studies.

Fifteen eligible studies were included in this meta-analysis. NSAIDs use was not associated with Parkinson disease risk [relevant risk (RR): 0.98; 95% confidence interval (95% CI), 0.95–1.02]. Subgroup analysis showed that aspirin use (RR: 1.14; 95% CI, 0.98–1.30) or ibuprofen use (RR: 1.01; 95% CI, 0.88–1.17) was not associated with Parkinson disease risk; however, the use of non-aspirin NSAIDs was significantly associated with Parkinson disease risk (RR: 0.91; 95% CI, 0.84–0.99). Furthermore, NSAIDs use was not associated with the risk of Parkinson disease in female (RR: 0.99; 95% CI, 0.83–1.17) and male (RR: 1.01; 95% CI, 0.88–1.16). In addition, a dose–response showed per 1 number of prescription incremental increase in NSAIDs use was not associated with the risk of Parkinson disease (RR: 0.96; 95% CI, 0.91–1.02), per 1 year of duration of NSAIDs use incremental increase was not associated with the risk of Parkinson disease (RR: 0.98; 95% CI, 0.92–1.03), and per 1 dosage of NSAIDs use incremental increase was not associated with the risk of Parkinson disease (RR: 0.98; 95% CI, 0.95–1.02).

NSAIDs use was not associated with the risk of Parkinson disease. The potency and the cumulative NSAIDs use did not play critical roles.

Abbreviations: CI = confidence interval, NSAIDs = nonsteroidal anti-inflammatory drugs, RRs = relevant risks.

Keywords: dose–response relationship, meta-analysis, NSAIDs, observational study, Parkinson disease

1. Introduction
Commonly known as nonsteroidal anti-inflammatory drugs (NSAIDs), they are widely used to eliminate pain, swelling, stiffness, and inflammation of the limbs, and they have been widely used in clinically.[1] In addition to anti-inflammatory, NSAIDs gradually attracts people’s attention in the prevention and treatment of Parkinson disease.[2] NSAIDs use is correlated with Parkinson disease and is biologically understandable. Neuroinflammation was correlated with the pathogenesis of Parkinson disease, and NSAIDs provide neuroprotection in animal models.[3,4]

It is estimated that there are more than 1 billion NSAIDs prescriptions in the world every year, and about 30 million people take NSAIDs every day.[5] The annual prescription of NSAIDs in the United States is about 70 million, accounting for 4% of all drug prescriptions.[6] In the UK, the prescription volume of NSAIDs is about 20 million, and 15% of the people over the age of 60 take NSAIDs.[7] Australia has about 11 million NSAIDs prescriptions per year, accounting for 5% of all drug prescriptions.[1] NSAIDs have been preliminarily proven to reduce the incidence of Alzheimer disease, which makes the application of NSAIDs uptrend.[8] Although NSAIDs use has a potential to prevent Parkinson disease, there have been safety concerns about their impact on Parkinson disease.[9,10] Currently, there are continued concerns, partly due to the conflicting results of the association between NSAIDs use and Parkinson disease.

Considering increasing number of patients being prescribed NSAIDs use, clinicians, pharmacists, patients, society, and governments pay more attention to the safety of these drugs. We conducted a meta-analysis based on observational studies to determine whether NSAIDs use is associated with Parkinson disease risk.

2. Methods
There are no ethical issues involved in our study for our data were based on published studies.

2.1. Search strategy
Eligible studies were systematically searched of Medline, Embase, Web of Science, and the Cochrane Database were searched update to November 2017 examining the association between NSAIDs use and Parkinson disease risk, with keywords, including “Parkinson Disease” [MeSH] or “PD” [MeSH] or “Lewy Body Parkinson’s disease” [MeSH] or “Idiopathic Parkinson’s Disease” [MeSH] and “NSAIDs” [MeSH] or “Non-Steroidal Anti-Inflammatory Agents” [MeSH] or “Anti-Inflammatory Analgesics” [MeSH] or “nonsteroidal anti-inflammatory drugs” [MeSH].
2.2. Inclusion and exclusion criteria

Investigators independently collect information: first, the outcome was Parkinson disease; second, risk estimates on the relationship between NSAIDs use and Parkinson disease risk. According to the Newcastle–Ottawa scale, quality assessment was performed for nonrandomized studies.\textsuperscript{[11]}

2.3. Statistical analysis

Due to different definitions of cut-off points in the included studies for categories, we performed a relative risk estimates by the method recommended by Orsini et al.\textsuperscript{[12]} In addition, use restricted cubic splines (RCS) to evaluate the nonlinear association between NSAIDs use and Parkinson disease risk, with 3 knots at the 10th, 50th, and 90th percentiles of the distribution. A flexible meta-regression based on RCS function was used to fit the potential nonlinear trend, and generalized least-square method was used to estimate the parameters. This procedure treats NSAIDs use (continuous data) as an independent variable and logRR of diseases as a dependent variable, with both tails of the curve restricted to linear. A $P$ value is calculated for linear or nonlinear by testing the null hypothesis that the coefficient of the second spline is equal to zero.

We use STATA software 14.0 (STATA Corp, College Station, TX) to evaluate the relationships between NSAIDs use and Parkinson disease risk. Heterogeneity among studies used $Q$ test and $I^2$ statistic to assess. If $P_Q < .10$ or $I^2 > 50\%$, random-effect model was chosen; otherwise, fixed-effect mode was applied. Begg and Egger tests were used to assess the publication bias of each study. $P < .05$ was considered significant for all tests.

3. Results

3.1. Literature search results

A total of 1115 studies from Medline, 1447 studies from Embase, and 1374 studies from Web of Science were included. After removing duplicates study, 1281 studies were identified. Reviewing their titles and abstracts, 1245 citations were excluded for no relevant outcome or nonhuman studies or reviews. The remaining 36 citations were assessed in more detail for eligibility by reading the full text. Among them, 19 studies were excluded due to lack of detailed information; 3 studies were excluded due to conference abstract. After review reference of studies, 1 article was identified. Finally, 15 studies were used for the final data synthesis.\textsuperscript{[13–27]} The flow chart of literature searching is presented in Fig. 1. The characteristics of the included studies are summarized in the Tables 1 and 2.

![Flow diagram of the study selection process.](Image)
### Table 1
Characteristics of participants in included studies of NSAIDs use in relation to risk of Parkinson disease.

| Ref.               | Study design          | Country     | Sex of population | Age at baseline, y | No of participants | Endpoints (cases) | Quality score |
|-------------------|-----------------------|-------------|-------------------|-------------------|--------------------|-------------------|---------------|
| Becker et al[26]  | Case-control          | UK          | Male and female   | ≥35               | 19,995             | Parkinson disease | 6             |
| Bornebroek et al[23] | Cohort                | Netherlands | Male and female   | ≥40               | 6512               | Parkinson disease | 6             |
| Bower et al[27]   | Case-control          | USA         | Male and female   | 71.0              | 302                | Parkinson disease | 6             |
| Chen et al[24]    | Cohort                | USA         | Male and female   | 40–75             | 142,902            | Parkinson disease | 8             |
| Chen et al[24]    | Cohort                | USA         | Male and female   | 75.0              | 146,948            | Parkinson disease | 8             |
| Driver et al[23]  | Nested case-control   | USA         | Male and female   | 40–84             | 22,007             | Parkinson disease | 8             |
| Etminan and Sussal[21] | Cohort                | Canada      | Male and female   | 73.9              | 13,849             | Parkinson disease | 7             |
| Hernán et al[17]  | Case                   | USA         | Male and female   | 46.5              | 697,078            | Parkinson disease | 7             |
| Gao et al[19]     | Cohort                | USA         | Male and female   | 40–75             | 136,197            | Parkinson disease | 7             |
| Hancock et al[18] | Case                   | USA         | Male and female   | 58.1              | 673                | Parkinson disease | 5             |
| Manthripragada et al[19] | Case-control          | Danish      | Male and female   | ≥35               | 11,582             | Parkinson disease | 5             |
| Powers et al[15]  | Case-control          | USA         | Male and female   | 69.6              | 2114              | Parkinson disease | 6             |
| Ton et al[16]     | Case-control          | USA         | Male and female   | 35–89             | 589                | Parkinson disease | 5             |
| Wahner et al[13]  | Case-control          | USA         | Male and female   | 70.0              | 579                | Parkinson disease | 5             |

### Table 2
Outcomes and covariates of included studies of NSAIDs use in relation to risk of Parkinson disease.

| Ref.               | Endpoints            | Data source       | Category and relative risk (95% CI) | Covariates in fully adjusted model                                                                 |
|-------------------|----------------------|-------------------|------------------------------------|--------------------------------------------------------------------------------------------------|
| Becker et al[26]  | Parkinson disease (4026) | Population-based | Number of prescription             | Adjusted for body mass index, smoking, asthma/chronic obstructive pulmonary disease, diabetes, congestive heart failure, hypertension, ischemic heart disease, stroke/transient ischemic attack, dementia |
| Bornebroek et al[23] | Parkinson disease (88) | Population-based | Duration of use                     | Adjusted for age, sex, smoking, and coffee consumption                                           |
| Chen et al[24]    | Parkinson disease (415) | Self-administered | Duration of use                     | Adjusted for age, smoking, past smoker, current smoker, caffeine intake, and alcohol consumption |
| Driver et al[23]  | Parkinson disease (565) | Self-administered | Duration of use                     | Adjusted for age, smoking (never, past, current), alcohol (weekly, monthly), body mass index (<25, 25–<30, ≥30), exercise to sweat (ever v never) |
| Hernán et al[17]  | Parkinson disease (1258) | Self-administered | Duration of use                     | Adjusted for age                                                                                  |
| Manthripragada et al[19] | Parkinson disease (1931) | Self-administered | Number of prescriptions             | Adjusting for age, sex, 5-y lagged COPD, 5-y lagged cardiovascular disease, and 5-y lagged Charlson index |

(continued)
Table 2 (continued).

| Ref.            | Endpoints       | Data source  | Category and relative risk (95% CI) Covariates in fully adjusted model |
|-----------------|-----------------|--------------|----------------------------------------------------------------------------|
| Powers et al\[15\] | Parkinson disease (1186) | Self-administered | Duration of use  
Never use, 1.0 (reference); 0–1.5 y, 0.80 (0.62–1.04); 1.5–3 y, 0.75 (0.58–0.97); >3 y, 0.98 (0.75–1.27)  
Number of prescription  
Never use, 1.0 (reference); 0–1.5 y, 0.80 (0.62–1.04); 1.5–3 y, 0.75 (0.58–0.97); >3 y, 0.98 (0.75–1.27)  
Adjusted for smoking, coffee, age, ethnicity, and state (and gender for men and women combined) |
| Ton et al\[14\]  | Parkinson disease (206) | Self-administered | Exposure restricted to 1 January 1977 to December 31, 1992  
Nonaspirin NSAIDs  
No use, 1.0 (reference); 1 Rx, 0.70 (0.38–1.29); 2 Rx, 0.59 (0.25–1.37); 3–9 Rx, 1.17 (0.70–1.96); >10 Rx, 0.90 (0.50–1.62)  
Exposure restricted to January 1, 1993, to October 1, 2002  
Nonaspirin NSAIDs  
No use, 1.0 (reference); 1 Rx, 1.94 (0.43–8.89); >2 Rx, 1.49 (0.39–5.69)  
Aspirin  
No use, 1.0 (reference); 0–3 Rx, 0.56 (0.23–1.33); 3–5 Rx, 0.86 (0.46–1.59); 6–13 Rx, 0.72 (0.37–1.43); >14 Rx, 0.76 (0.39–1.47)  
Adjusted for age, sex, smoking, duration of enrollment, and clinic |
| Wahner et al\[13\] | Parkinson disease (293) | Population-based | Duration of use  
Nonaspirin NSAIDs  
Never use, 1.0 (reference); <1 y, 0.65 (0.37–1.14); >1 y, 0.44 (0.26–0.74)  
Aspirin  
Never use, 1.0 (reference); <1 y, 0.89 (0.54–1.47); >1 y, 0.75 (0.49–1.15)  
Dosage of NSAIDs  
Nonaspirin NSAIDs  
Never use, 1.0 (reference); 2–14 tablets/wk, 0.38 (0.21–0.67); >14 tablets/wk, 0.68 (0.41–1.13)  
Aspirin  
Never use, 1.0 (reference); 2–14 tablets/wk, 0.81 (0.54–1.18); >14 tablets/wk, 0.80 (0.43–1.48)  
Adjusted for gender, race, age at diagnosis, smoking pack-years, education, and regular other nonsteroidal anti-inflammatory drugs use |
| Gao et al\[19\]  | Parkinson disease (291) | Population-based | Dosage of NSAIDs  
Ibuprofen  
Never use, 1.0 (reference); 1–2 tablets/wk, 0.85 (0.45–1.66); 3–5 tablets/wk, 0.40 (0.15–1.08); >6 tablets/wk, 0.55 (0.29–1.03)  
Aspirin  
Never use, 1.0 (reference); 1–2 tablets/wk, 0.77 (0.50–1.16); 3–5 tablets/wk, 1.11 (0.73–1.67); >6 tablets/wk, 1.05 (0.78–1.41)  
Acetaminophen  
Never use, 1.0 (reference); 1–2 tablets/wk, 1.04 (0.57–1.88); 3–5 tablets/wk, 1.03 (0.57–1.96); >6 tablets/wk, 0.69 (0.37–1.14)  
Adjusted for age, smoking status, body mass index, intake of caffeine, lactose, and alcohol |
| Chen et al\[24\]  | Parkinson disease (413) | Population-based | Dosage of NSAIDs  
Ibuprofen  
Never use, 1.0 (reference); 0–2 tablets/wk, 1.01 (0.73–1.41); 2–6 tablets/wk, 1.34 (1.04–1.74); >7 tablets/wk, 1.01 (0.78–1.31)  
Aspirin  
Never use, 1.0 (reference); 0–2 tablets/wk, 0.73 (0.49–1.08); 2–6 tablets/wk, 0.72 (0.44–1.17); >7 tablets/wk, 0.62 (0.37–1.02)  
Other NSAIDs  
Never use, 1.0 (reference); 0–2 tablets/wk, 0.91 (0.45–1.84); 2–6 tablets/wk, 1.01 (0.50–2.04); >7 tablets/wk, 0.98 (0.60–1.60)  
Adjusted for age, sex, and smoking |

CI = confidence interval, COPD = chronic obstructive pulmonary disease, NSAIDs = nonsteroidal anti-inflammatory drugs.
3.2. NSAIDs use and Parkinson disease risk

Fifteen eligible studies including 25 independent reports identified the relationship between NSAIDs use and Parkinson disease risk. NSAIDs use was not associated with Parkinson disease risk [relevant risk (RR): 0.96; 95% confidence interval (95% CI), 0.91–1.02; \( P = .174 \)] (Table 3). Subgroup analysis showed that aspirin use (RR: 1.03; 95% CI, 0.95–1.11; \( P = .502 \)) (Table 3) or ibuprofen use (RR: 0.87; 95% CI, 0.70–1.08; \( P = .010 \)) (Table 3) was not associated with Parkinson disease risk; however, nonaspirin NSAIDs use was significantly associated with Parkinson disease risk decrement (RR: 0.91; 95% CI, 0.84–0.99; \( P = .028 \)) (Table 3). Furthermore, NSAIDs use was not associated with Parkinson disease risk in female (RR: 0.99; 95% CI, 0.83–1.17; \( P = .876 \)) (Table 3) and male (RR: 1.01; 95% CI, 0.88–1.16; \( P = .913 \)) (Table 3).

3.3. Dose–response between NSAIDs use and risk of Parkinson disease

A dose–response showed that per 1 number of prescription incremental increase in NSAIDs use was not associated with Parkinson disease risk (RR: 0.96; 95% CI, 0.91–1.02; \( P = .513 \)) (Fig. 2), per 1 year of duration of NSAIDs use incremental

---

### Table 3

| Stratification variable               | No. of reports | Relative risk (95% CI) | \( P \) | \( I^2 \) (%) | \( P \) for test |
|---------------------------------------|----------------|------------------------|--------|---------------|-----------------|
| Total                                 | 25             | 0.96 (0.91–1.02)       | .026   | 38.9%         | .174            |
| Class of NSAIDs drug                  |                |                        |        |               |                 |
| Nonaspirin NSAIDs                     | 10             | 0.91 (0.84–0.99)       | .106   | 37.9%         | .028            |
| Aspirin                               | 10             | 1.03 (0.95–1.11)       | .502   | 0.0%          | .467            |
| Ibuprofen                             | 5              | 0.87 (0.70–1.08)       | .010   | 69.8%         | .204            |
| Gender                                |                |                        |        |               |                 |
| Female                                | 8              | 0.99 (0.83–1.17)       | .043   | 51.8%         | .876            |
| Male                                  | 10             | 1.01 (0.88–1.16)       | .007   | 60.4%         | .913            |
| Study design                          |                |                        |        |               |                 |
| Case–control                          | 17             | 0.95 (0.90–1.01)       | .033   | 54.1%         | .981            |
| Cohort                                | 8              | 1.00 (0.87–1.16)       | .095   | 32.7%         | .075            |
| Study quality                         |                |                        |        |               |                 |
| Score ≥7                              | 8              | 1.00 (0.87–1.16)       | .096   | 32.7%         | .075            |
| Score <7                              | 17             | 0.95 (0.90–1.01)       | .033   | 54.1%         | .981            |
| No. of participants                   |                |                        |        |               |                 |
| ≥10,000                               | 13             | 0.98 (0.92–1.03)       | .194   | 42.8%         | .370            |
| <10,000                               | 12             | 0.91 (0.79–1.01)       | .036   | 47.0%         | .110            |
| No. of cases                          |                |                        |        |               |                 |
| ≥500                                  | 9              | 0.97 (0.91–1.03)       | .373   | 7.4%          | .273            |
| <500                                  | 16             | 0.94 (0.83–1.07)       | .011   | 50.7%         | .362            |

CI = confidence interval, NSAIDs = nonsteroidal anti-inflammatory drugs.
increase was not associated with Parkinson disease risk (RR: 0.98; 95% CI, 0.92–1.03; \( P = 0.404 \)) (Fig. 3), and per 1 dosage of NSAIDs use incremental increase was not associated with Parkinson disease risk (RR: 0.98; 95% CI, 0.95–1.02; \( P = .103 \)) (Fig. 4).

3.4. Publication bias
Statistical tests suggest that there was no evidence of publication bias [Begg test \( P = .44 \) and Egger test \( P = .56 \)] (Supplementary table 1, http://links.lww.com/MD/C476). A funnel plot for publication bias assessment is illustrated in supplementary figure 1 to 3, http://links.lww.com/MD/C476.

4. Discussion
Parkinson disease, also known as tremor paralysis, is one of the most common neurodegenerative diseases, and slow motion, myotonia, tremor, abnormal gait, cognitive disorders, sleep disorders, autonomic dysfunction, and sensory disorders are the main features of this disease.\[^{28,29}\] There is no specific treatment for Parkinson disease.\[^{30}\] The treatment of Parkinson disease is
mainly from reducing the pain, delaying the development of the disease, and improving the quality of life of the patients. Although some of the drugs (such as cholinesterase inhibitors) can improve the ability of patients to accept new things in short term and delay the aggravation of Parkinson disease, the long-term curative effect remains to be observed. Antipsychotic drugs can be used to combat psychotic symptoms, agitation, or aggressive behavior. Antidepressants can be used in patients with dementia and depression, and help to improve the dementia syndrome. But it must be noted that the anticholinergic side effects of tricyclic drugs can aggravate cognitive impairment. Although benzodiazepines use can control the behavior problem of the Parkinson disease, it should be specially cautious because it can cause falls and drug dependence. These drugs in the treatment of Parkinson disease more or less have some kinds of problems, and NSAIDs have been widely used in anti-inflammatory therapy, and their pleiotropic effects have expanded its clinical value and the potential therapeutic effect of NSAIDs on Parkinson disease is expected.

NSAIDs are a class of drugs that eliminate prostaglandin synthetase to eliminate inflammation. A variety of evidence suggests that inflammation contributes to the pathogenesis of Parkinson disease; NSAIDs have a potential therapeutic effect on Parkinson disease, although it has an anti-inflammatory effect. However, the relationship between NSAIDs use and Parkinson disease is inconclusive. Among these selected studies, most of the reports have found NSAIDs use was not associated with Parkinson disease, but one report found that NSAIDs use was associated with Parkinson disease risk decrement. Two reports found nonaspirin NSAIDs was associated with Parkinson disease risk decrement, and either no effect or increased Parkinson disease risk. Aspirin use was not associated with a decreased risk of Parkinson disease in all studies. Ibuprofen use was slightly associated with Parkinson disease risk decrement in 2 studies.

Two meta-analyses have identified the relationship between NSAID use and Parkinson disease risk, but presented controversial results. Gagne and Power, based on seven observational studies, found nonaspirin NSAIDs use was associated with Parkinson disease risk decrement (RR: 0.85; 95% CI, 0.77–0.94), and aspirin was not associated with Parkinson disease risk (RR: 1.08; 95% CI, 0.92–1.27). However, Samii et al. based on 11 observational studies, found NSAIDs use (RR: 0.95; 95% CI, 0.80–1.12) and aspirin (RR: 1.08; 95% CI, 0.93–1.26) was not associated with risk of Parkinson disease, but ibuprofen use was slightly associated with Parkinson disease risk decrement (RR: 0.76; 95% CI, 0.65–0.89). Also, Samii et al. found that NSAIDs use was associated with Parkinson disease risk decrement in male (RR: 0.79; 95% CI, 0.69–0.92) but not female (RR: 0.72; 95% CI, 0.45–1.15).

Considering these conflicting results, this meta-analysis was based on the latest evidence update to November 2017 from 15 studies supporting that NSAIDs use was not associated with the risk of Parkinson disease, and a dose–response showed per 1 number of prescription incremental increase in NSAIDs use was not associated with risk of Parkinson disease (RR: 0.96; 95% CI, 0.91–1.02), per 1 year of duration of NSAIDs use incremental increase was not associated with risk of Parkinson disease (RR: 0.93; 95% CI, 0.89–0.97), and per 1 dosage of NSAIDs use incremental increase was not associated with risk of Parkinson disease (RR: 0.98; 95% CI, 0.95–1.02); the potency and the cumulative NSAIDs use did not play critical roles. This meta-analysis included enough studies; these results should be credible.

This meta-analysis also has some limitations. First, we have never tried to search for unpublished research, which may lead to the disappearance of related research. Second, we did not include randomized controlled trials due to Parkinson disease, which was not a prespecified endpoint in randomized controlled trials; on the contrary, test results of the NSAIDs use statistical heterogeneity were limited in randomized controlled trials, and limited evidence of a dose-dependent association between NSAIDs and Parkinson disease risk provides limited confidence in their findings, and randomized controlled trials should be included in further studies.

This meta-analysis indicates that that NSAIDs use was not associated with risk of Parkinson disease. The potency and the cumulative NSAIDs use did not play critical roles. In the future, large-scale and population-based association studies must be performed in the future to validate the risk identified in the current meta-analysis.

Author contributions

Data curation: Li Ren, Jie Yi, Xueyan Cheng, Peixian Mao.

Formal analysis: Jie Yi, Peixian Mao.

Investigation: Peng Li, Peixian Mao.

Project administration: Peng Li.

Software: Li Ren, Jing Yang, Peixian Mao.

Writing – original draft: Peixian Mao.

Writing – review & editing: Peixian Mao.

References

[1] Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 2016;15:1257–72.

[2] Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 2001;39:167–74.

[3] Hirsch E, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 2009;8:382–97.

[4] Hunot S, Hirsch E. Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 2003;53 suppl 3:S59–58. discussion S58-S60.

[5] Lanas A, Hirschowitz B. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999;11:375–81.

[6] Raskin J. Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999;106:3S–12S.

[7] Shin S, Noh C, Lim S, et al. Non-steroidal anti-inflammatory drug-induced enteropathy. Intest Res 2017;15:446–55.

[8] Miguel-Álvarez M, Santos-Lozano A, Sanchis-Gomar F, et al. Nonsteroidal anti-inflammatory drugs as a treatment for Alzheimer’s disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 2013;32:139–47.

[9] Chen H, Jacobs E, Schwarzschild M, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 2005;58:363–7.

[10] Chen H, Zhang S, Hernán M, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2005;62:1059–64.

[11] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.

[12] Orsini N, Li R, Wolk A, et al. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012;175:66–73.

[13] Wahner AD, Bronstein JM, Bordelon YM, et al. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007;69:1836–42.

[14] Ton TG, Heckbert SR, Longstreth WT Jr, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease. Mov Disord 2006;21:964–9.

[15] Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, caffeine, and NSAIDs on Parkinson’s disease risk. Mov Disord 2008;23:88–95.

[16] Manthrpragada AD, Schernhammer ES, Qiu J, et al. Non-steroidal anti-inflammatory drug use and the risk of Parkinson’s disease. Neuroepidemiology 2011;36:135–61.
[17] Hernan MA, Logroscino G, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006;66:1097–9.

[18] Hancock DB, Martin ER, Staich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007;64:576–80.

[19] Gao X, Chen H, Schwarzschild MA, et al. Use of ibuprofen and risk of Parkinson disease. Neurology 2011;76:863–9.

[20] Erminan M, Carleton BC, Samii A. Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 2008;15:576–7.

[21] Erminan M, Suisse S. NSAID use and the risk of Parkinson’s disease. Curr Drug Saf 2006;1:223–5.

[22] Driver JA, Logroscino G, Lu L, et al. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study. BMJ (Clinical research ed) 2011;342:d198.

[23] Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059–64.

[24] Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal anti-inflammatory drug use and the risk for Parkinson’s disease. Ann Neurol 2005;58:963–7.

[25] Bornebroek M, de Lau L, Haag M, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007;28:193–6.

[26] Becker C, Jick S, Meier C. NSAID use and risk of Parkinson disease: a population-based case-control study. Eur J Neurol 2011;18:1336–42.

[27] Bower JH, Maraganore DM, Peterson BJ, et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006;67:494–6.

[28] Driver JA, Kurth T, Buring JE, et al. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008;70:1423–30.

[29] Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384–6.

[30] Ritchie K, Lovestone S. The dementias. Lancet (London, England) 2002;360:1759–66.

[31] Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003;2:539–47.

[32] Mathos MV, Miusio BM, Andreason P, et al. The US Food and Drug Administration’s perspective on the new antipsychotic pimavanserin. J Clin Psychiatry 2017;78:e668–73.

[33] American Psychiatric Association Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997;154(5 suppl):1–39.

[34] Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther 2006;79:9–19.

[35] Esposito E, Di Matteo V, Benigno A, et al. Non-steroidal anti-inflammatory drugs in Parkinson’s disease. Exp Neurol 2007;205: 295–312.

[36] Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010;74:995–1002.

[37] Samii A, Erminan M, Wiens MO, et al. NSAID use and the risk of Parkinson’s disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009;26:769–79.